Total Injury Help

Time is LIMITED to File!

ATTENTION: Dupixent Patients Diagnosed with Skin Lymphoma

Many patients prescribed Dupixent® (dupilumab) for eczema, asthma, or related conditions have developed rare forms of skin cancer, which are now under FDA safety review.


If you or a loved one used Dupixent for 30 days or more, you may be entitled to significant compensation.


ATTENTION: Dupixent Patients Diagnosed with Skin Lymphoma

Many patients who used Dupixent (dupilumab) for eczema or asthma have developed rare skin cancers, which are now under FDA review.


If you or a loved one used Dupixent for 30+ days, you may be entitled to significant compensation.

Total Injury Help has helped thousands of patients nationwide impacted by dangerous and misleading pharmaceutical products.


If you or a loved one developed Cutaneous T-Cell Lymphoma (CTCL), Sézary Syndrome, or Mycosis Fungoides after using Dupixent, you may be eligible for compensation related to:

Medical Costs: Treatment for Cutaneous T-Cell Lymphoma can exceed $120,000–$250,000 per year, including biopsies, phototherapy, systemic medications, and oncology care.

Loss of Lifestyle: Many Dupixent patients diagnosed with CTCL or related lymphomas face extended medical leave, job loss, or limited mobility due to treatment side effects and disease progression.

Emotional Damages: A cancer diagnosis brings severe emotional distress for both patients and families. You may qualify for additional compensation related to pain, anxiety, and loss of quality of life caused by Dupixent-related harm.

Get the financial support you deserve while you focus on your recovery and family.


See if you qualify today!

You Deserved to Know the Risks of Dupixent

A 2024 medical study found that patients treated with Dupixent were over 300% more likely to be diagnosed with a rare form of skin lymphoma compared to non-users.

  • Dupixent (dupilumab) is a biologic injection used for eczema, asthma, and related conditions. It works by suppressing immune pathways that control inflammation (IL-4 and IL-13).
  • Researchers observed an increased rate of serious conditions like Cutaneous T-Cell Lymphoma (CTCL), Sézary Syndrome, and Mycosis Fungoides among Dupixent patients.
  • Experts believe Dupixent may unmask or accelerate skin lymphomas in some individuals, prompting the FDA to monitor the drug for potential safety concerns.

Find Out Now If You Qualify for a Dupixent Case

There is no upfront cost, and your consultation is 100% free and confidential.

See if I Qualify for Compensation